イエダニアレルギー治療薬の世界市場2022

Global Markets Directが発行した調査報告書(GMDHC22045IDB)
◆英語タイトル:House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
◆商品コード:GMDHC22045IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2022年3月
◆ページ数:52
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥280,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥840,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、開発中のイエダニアレルギー治療薬市場について調査・分析し、イエダニアレルギー概要、治療薬開発、パイプライン概要、企業別のパイプライン、大学/機関別のパイプライン、企業別の開発中製品、大学/機関別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。 
・イエダニアレルギー-概要
・イエダニアレルギー-治療薬開発
・パイプライン概要
・企業別のパイプライン
・大学/機関別のパイプライン
・企業別の開発中製品
・大学/機関別の開発中製品
・イエダニアレルギー-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・イエダニアレルギー-治療薬開発に携わる企業
❖ レポートの概要 ❖

House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 3, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

❖ レポートの目次 ❖

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy – Overview
House Dust Mite Allergy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
House Dust Mite Allergy – Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy – Companies Involved in Therapeutics Development
Advagene Biopharma Co Ltd
ALK-Abello AS
Allergy Therapeutics Plc
Astellas Pharma Inc
Genetic Immunity Inc
Roxall Medizin GmbH
Stallergenes Greer Ltd
Worg Pharmaceuticals Hangzhou Co Ltd
House Dust Mite Allergy – Drug Profiles
AD-17002 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-2390 – Drug Profile
Product Description
Mechanism Of Action
History of Events
clustoid d. pteronyssinus – Drug Profile
Product Description
Mechanism Of Action
DermAll-HDM – Drug Profile
Product Description
Mechanism Of Action
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract – Drug Profile
Product Description
Mechanism Of Action
History of Events
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract – Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Grass Pollen Allergy and House Dust Mite Allergy – Drug Profile
Product Description
Mechanism Of Action
Vaccine for House Dust Mite Allergy – Drug Profile
Product Description
Mechanism Of Action
Vaccine for House Dust Mite Allergy – Drug Profile
Product Description
Mechanism Of Action
WP-1049 – Drug Profile
Product Description
Mechanism Of Action
House Dust Mite Allergy – Dormant Projects
House Dust Mite Allergy – Discontinued Products
House Dust Mite Allergy – Product Development Milestones
Featured News & Press Releases
May 31, 2021: Positive outcome of European decentralised registration procedure for Stallergenes Greer’s sublingual house dust mite allergen immunotherapy tablet
May 04, 2020: Stallergenes Greer submits a marketing authorisation application in Europe for its sublingual house dust mite allergen immunotherapy tablet
Jan 13, 2020: New clinical trial for ALK’s house dust mite tablet paves the way for early registration in China
Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears
May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial
Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint
May 29, 2018: Allergy Therapeutics – Positive new data with house-dust mite immunotherapy
Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
Feb 16, 2018: Torii Receives Approval for Additional Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets
Jan 11, 2018: New Treatment for House Dust Mite (HDM) – Induced Allergic Rhinitis Now Available in US
Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France
Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval
Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Canada
Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for House Dust Mite Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
House Dust Mite Allergy - Pipeline by Advagene Biopharma Co Ltd, 2022
House Dust Mite Allergy - Pipeline by ALK-Abello AS, 2022
House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, 2022
House Dust Mite Allergy - Pipeline by Astellas Pharma Inc, 2022
House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, 2022
House Dust Mite Allergy - Pipeline by Roxall Medizin GmbH, 2022
House Dust Mite Allergy - Pipeline by Stallergenes Greer Ltd, 2022
House Dust Mite Allergy - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022
House Dust Mite Allergy - Dormant Projects, 2022
House Dust Mite Allergy - Discontinued Products, 2022

List of Figures
Number of Products under Development for House Dust Mite Allergy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ イエダニアレルギー治療薬の世界市場2022(House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆